GSK plc (NYSE:GSK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of GSK plc (NYSE:GSK) have received a consensus rating of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and three have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $43.25.

Several analysts recently commented on the company. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a report on Sunday. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st.

GSK Stock Up 1.4 %

Shares of GSK stock opened at $33.93 on Tuesday. GSK has a twelve month low of $32.83 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company’s 50 day moving average is $34.67 and its 200 day moving average is $38.35. The company has a market cap of $70.32 billion, a price-to-earnings ratio of 22.03, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.63%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio (DPR) is presently 98.70%.

Institutional Investors Weigh In On GSK

Several large investors have recently bought and sold shares of GSK. Eastern Bank bought a new position in GSK during the 3rd quarter valued at about $26,000. Sunbelt Securities Inc. increased its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners raised its position in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of GSK in the 2nd quarter worth $37,000. Finally, Fortitude Family Office LLC bought a new position in shares of GSK during the 3rd quarter worth $42,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.